Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Curr Protein Pept Sci. 2020;21(7):699–712. doi: 10.2174/1389203721666200507091952

Table 2.

PRMT Inhibitors in Clinical Trials.

Name Target Company Starting date Phase Treated cancer Clinical trial identifier
JNJ46419178 PRMT5 Janssen Jul-18 Phase I Solid tumor, adult NHL, and myelodysplastic syndromes NCT03573310 [127]
GSK3368715 Type I PRMTs GlaxoSmithKline Oct-18 Phase I Solid tumors and DLBCL NCT03666988 [126]
GSK3326595 PRMT5 GlaxoSmithKline Aug-16 Phase I Solid tumors and NHL NCT02783300 [128]
GSK3326595 PRMT5 GlaxoSmithKline Oct-18 Phase II Myelodysplastic syndrome and acute myeloid leukemia NCT03614728 [129]
PF-06939999 PRMT5 Pfizer Mar-19 Phase I Advanced solid tumors NCT038544227 [130]